-
Promising Breakthrough: Johnson & Johnson Reports Strong Data for Pasritamig in Prostate Cancer Treatment
NYSE: $JNJ A New Frontier in Prostate Cancer Research In a significant development for oncology, Johnson & Johnson has released positive results from its clinical trials concerning an investigational immunotherapy drug known as pasritamig. The findings, which focus on its application in treating prostate-specific antigen (PSA) levels, offer a glimmer of hope for patients facing…
-
Jemperli (dostarlimab-gxly) Approved in US as First and Only Immunotherapy for Adults with MSI-H/dMMR Locally Advanced Rectal Cancer
NYSE: $GSK Philadelphia, PA — October 19 2026 — GSK plc (LSE/NYSE: GSK) today announced the US Food and Drug Administration (FDA) has approved Jemperli (dostarlimab-gxly) as the first and only immunotherapy for adults with stage II and III microsatellite… Source: Read More
-
New Hope: FDA Expands Approval for Anktiva in Bladder Cancer Treatment
NASDAQ: $IBRX A Major Milestone in Bladder Cancer Care The landscape for treating non-muscle invasive bladder cancer (NMIBC) has just seen a significant shift. The FDA has officially expanded the approval of Anktiva (nogapendekin alfa inbakicept-pmln), providing a new, vital option for patients facing one of the most challenging forms of this disease. Understanding the…
-
A New Frontier in Colon Cancer: First Patient Dosed in Phase III Cadonilimab Trial
Advancing Immunotherapy for Colon Cancer In a significant milestone for oncology research, Akeso, Inc. has officially announced that the first patient has been dosed in a global Phase III clinical trial evaluating cadonilimab. This study focuses on the perioperative treatment of patients with locally advanced colon cancer. Understanding Cadonilimab Cadonilimab is a novel, potentially first-in-class…
-
A New Hope for Peanut Allergy Sufferers: FDA Grants Fast Track Designation to PVX108
Revolutionizing Peanut Allergy Treatment For millions of people living with a peanut allergy, even accidental exposure can cause life-threatening reactions. Recently, the biotechnology company Aravax reached a major milestone in the fight to change this reality. The U.S. Food and Drug Administration (FDA) has officially granted Fast Track designation to the company’s lead investigational product,…
-
A New Hope: FDA Grants Priority Review for Jemperli in Locally Advanced Rectal Cancer
NYSE: $GSK Advancing Treatment for dMMR/MSI-H Rectal Cancer There is promising news in the landscape of oncology as the U.S. Food and Drug Administration (FDA) has officially accepted a supplemental Biologics License Application (sBLA) for Jemperli (dostarlimab-gxly). This application has been granted Priority Review, signaling a potential shift in how we approach locally advanced rectal…
-
A New Frontier: FDA Approves Imfinzi for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
A Significant Breakthrough in Bladder Cancer Care For patients facing non-muscle invasive bladder cancer (NMIBC), treatment options have historically been limited, particularly for those whose cancer does not respond to standard BCG therapy. Recently, the landscape of care shifted with the FDA approval of Imfinzi (durvalumab), marking a major milestone as the first and only…
-
IDEAYA Biosciences Enters Exclusive License with Hengrui Pharma for SHR-4849, a Novel Phase 1 DLL3 Topo-I-Payload ADC Targeting SCLC and NET Solid Tumors
NASDAQ: $IDYA IDEAYA Biosciences’ recent exclusive license agreement with Hengrui Pharma for SHR-4849 marks a significant milestone in the field of oncology therapeutics. This partnership brings forth a promising novel Phase 1 DLL3 Topo-I-Payload Antibody-Drug Conjugate (ADC) targeting Small Cell Lung Cancer (SCLC) and Neuroendocrine Tumors (NET). The collaboration between these two renowned pharmaceutical companies…
-
Cullinan Oncology Announces First Patient Dosed in Phase 1 Trial Evaluating CLN-617, a Novel Fusion Protein Uniquely Harnessing Both IL-2 and IL-12 Cytokines
NASDAQ: $CGEM 1. Introduction to CLN-617: A Novel Fusion Protein The field of oncology research continues to evolve with the aim of developing innovative and effective therapies to combat cancer. In this regard, Cullinan Oncology has recently announced the initiation of a Phase 1 clinical trial to evaluate the potential of CLN-617, a novel fusion…